CADUS PHARMACEUTICAL CORP
10-Q, EX-27, 2000-08-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: CADUS PHARMACEUTICAL CORP, 10-Q, 2000-08-14
Next: EQUITY MARKETING INC, 10-Q, 2000-08-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the Balance
Sheet, and Income Statement and is qualified in its entirety by reference to
such financial statements.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>               DEC-31-2000
<PERIOD-END>                    JUN-30-2000
<CASH>                            5,268,807
<SECURITIES>                              0
<RECEIVABLES>                             0
<ALLOWANCES>                              0
<INVENTORY>                               0
<CURRENT-ASSETS>                  5,340,765
<PP&E>                                    0
<DEPRECIATION>                            0
<TOTAL-ASSETS>                   26,320,667
<CURRENT-LIABILITIES>               109,193
<BONDS>                                   0
               132,857
                               0
<COMMON>                                  0
<OTHER-SE>                        6,517,172
<TOTAL-LIABILITY-AND-EQUITY>     26,320,667
<SALES>                                   0
<TOTAL-REVENUES>                    700,000
<CGS>                                     0
<TOTAL-COSTS>                             0
<OTHER-EXPENSES>                  1,200,092
<LOSS-PROVISION>                          0
<INTEREST-EXPENSE>                        0
<INCOME-PRETAX>                    (970,989)
<INCOME-TAX>                              0
<INCOME-CONTINUING>                (970,989)
<DISCONTINUED>                            0
<EXTRAORDINARY>                           0
<CHANGES>                                 0
<NET-INCOME>                       (970,989)
<EPS-BASIC>                           (0.07)
<EPS-DILUTED>                         (0.07)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission